Search

Your search keyword '"Polidoro, L."' showing total 68 results
Start Over Author "Polidoro, L."
68 results on '"Polidoro, L."'

1. Un frammento di cratere neoattico da Milano

Author

Sacchi, F, Polidoro, L, Sacchi, Furio, Sacchi, F (ORCID:0000-0003-1088-0083), Sacchi, F, Polidoro, L, Sacchi, Furio, and Sacchi, F (ORCID:0000-0003-1088-0083)

Abstract

Il volume raccoglie una serie di contributi dedicate a scoperte recenti o edizioni di vecchi scavi e materiali da Milano e territorio metropolitano

Published
2024

2. Tubuli fittili da riscaldamento

Author

Gorla, D, Polidoro L., Pintaudi L., Marchisio R., Matteoni F., Cervo S., Bona A., Uboldi M., Sacchi, F., Marta, G., Grassi, E., Sannazaro, M., Sedini, E., Vignola, M., Casirani, M., Valente, R., F. Sacchi, D. Gorla, Sacchi, Furio, Sacchi, F. (ORCID:0000-0003-1088-0083), Gorla, D, Polidoro L., Pintaudi L., Marchisio R., Matteoni F., Cervo S., Bona A., Uboldi M., Sacchi, F., Marta, G., Grassi, E., Sannazaro, M., Sedini, E., Vignola, M., Casirani, M., Valente, R., F. Sacchi, D. Gorla, Sacchi, Furio, and Sacchi, F. (ORCID:0000-0003-1088-0083)

Abstract

Il contributo analizza i tubli fittili da riscaldamento rinvenuti nella villa tardoantica di Palazzo Pignano cercando di tracciare un quadro della presenza di questa classe in Lombardia

Published
2020

6. Massimiano e le sue terme

Author

Sacchi, F, Parodi, A, Polidoro, L, Fedeli, A, Gorla, D, Marchisio, R, Gelfi, N, Sacchi, Furio, Sacchi Furio (ORCID:0000-0003-1088-0083), Sacchi, F, Parodi, A, Polidoro, L, Fedeli, A, Gorla, D, Marchisio, R, Gelfi, N, Sacchi, Furio, and Sacchi Furio (ORCID:0000-0003-1088-0083)

Abstract

Nel volume si analizza il complesso delle Terme imperiali tardoantiche di Milano, con particolare attenzioni ai litotipi utilizzati per la decorazione degli interni

Published
2019

9. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial

Author

Vaccaro, O, Masulli, M, Bonora, E, Del Prato, S, Giorda, Cb, Maggioni, Ap, Mocarelli, P, Nicolucci, A, Rivellese, Aa, Squatrito, S, Riccardi, G, IT study group, T. O. S. C. A., Sud, Cm, Imbaro, S, Garofalo, N, Ferrannini, E, Howard, B, Gerdts, E, Imperatore, G, Tavazzi, L, Pellegrini, F, Fabbri, G, Levantesi, G, Turazza, F, Gentile, S, Panico, S, Brambilla, P, Signorini, S, Cappellini, F, Parma, C, D'Alonzo, D, Di Nardo, B, Ferrari, S, Franciosi, M, Pecce, R, Valentini, M, Ceseri, M, Bianchini, F, Baldini, E, Atzori, A, Boemi, M, D'Angelo, F, Giansanti, R, Ricci, L, Ranchelli, A, Di Berardino, P, Cannarsa, E, Giorgino, F, Manicone, M, Tarantino, L, Trevisan, R, Scaranna, C, Forlani, G, Montesi, L, Aiello, A, Barrea, A, Sinagra, T, Longhitano, S, Sesti, G, Gnasso, A, Carallo, C, Scicchitano, C, Santini, C, Calbucci, G, Ripani, R, Corsi, L, Corsi, S, Romeo, F, Asprino, V, Donnarumma, G, Tizio, B, Clemente, G, Tomasi, F, Dozio, N, Mannucci, E, Lamanna, C, Cignarelli, M, Macchia, Ol, Fariello, S, Cordera, R, Mazzucchelli, C, Pupillo, M, Zugaro, A, Bosco, A, De Luca, A, Iannarelli, R, Giuliani, A, Polidoro, L, Sperandio, A, Sciarretta, F, Raffaella, B, Venditti, C, Di Cianni, G, Goretti, C, Dolci, Ma, Bruselli, L, Mori, M, Baccetti, F, Gregori, G, Venezia, A, Cucinotta, D, Pintaudi, B, Ragonese, F, Pata, P, Piatti, Pm, Luccotti, P, Orsi, E, Bonomo, M, Menicatti, L, Turco, Aa, Ciano, O, Vallefuoco, P, Corigliano, G, Pentangelo, C, Petraroli, E, Auletta, P, Carbonara, O, Capobianco, G, Caiazzo, G, Angiulli, B, De Simone, G, Michele, C, Mastrilli, V, Nunziata, G, Romano, G, Gaeta, I, Sorrentino, T, Iovine, C, Nappi, F, Paolisso, G, Rizzo, Mr, Avogaro, A, Vedovato, M, Lapolla, A, Sartore, G, Burlina, S, Chilelli, Nc, Galluzzoy, A, Giordano, C, Torregrossa, V, Arsenio, L, Dall'Aglio, E, Cioni, F, Babini, M, Moncastroppa, G, Perriello, G, Timi, A, Consoli, A, Ginestra, F, Zavaroni, D, Calzoni, F, Miccoli, R, Bianchi, C, Politi, S, Anichini, R, Tedeschi, A, Citro, G, Zampino, A, Rosa, S, Natale, M, Giocoli, Cl, Caruso, E, Tramontano, L, Imbroinise, A, Perna, Cd, Calabrese, M, Zogheri, A, Luberto, A, Ballardini, G, Babini, Ac, Zannoni, C, Pugliese, G, Salvi, L, Mazzitelli, G, Zappaterreno, A, Frontoni, S, Ventricini, A, Lauro, D, Galli, A, Rinaldi, Me, Leotta, S, Fontana, L, Goretti, S, Pozzilli, P, Leonetti, F, Morano, S, Filetti, S, Cosmo, Sd, Bacci, S, Palena, Ap, Calatola, P, Capuano, G, Amelia, U, Dotta, Francesco, Guarino, E, Ceccarelli, E, Lalli, C, Scarponi, M, Forte, E, Potenziani, S, Perin, Pc, Marena, S, Zucco, C, Perotto, M, Bossi, A, Filopanti, M, Grimaldi, F, Tonutti, L, Cavarape, A, Cigolini, M, Pichiri, I, Brangani, C, Tomasetto, E, Capra, C, Cigolini, M., Vaccaro, O1, Masulli, M, Bonora, E, Del Prato, S, Giorda, Cb, Maggioni, Ap, Mocarelli, P, Nicolucci, A, Rivellese, Aa, Squatrito, S, Riccardi, G, Collaborators Riccardi G, T. O. S. C. A. IT study g. r. o. u. p., Sud, Cm, Imbaro, S, Vaccaro, O, Garofalo, N, Ferrannini, E, Howard, B, Gerdts, E, Imperatore, G, Tavazzi, L, Pellegrini, F, Fabbri, G, Levantesi, G, Turazza, F, Gentile, Sandro, Panico, S, Brambilla, P, Signorini, S, Cappellini, F, Parma, C, D'Alonzo, D, Di Nardo, B, Ferrari, S, Franciosi, M, Pecce, R, Valentini, M, Ceseri, M, Bianchini, F, Baldini, E, Atzori, A, Boemi, M, D'Angelo, F, Giansanti, R, Ricci, L, Ranchelli, A, Di Berardino, P, Cannarsa, E, Giorgino, F, Manicone, M, Tarantino, L, Trevisan, R, Scaranna, C, Forlani, G, Montesi, L, Aiello, A, Barrea, A, Sinagra, T, Longhitano, S, Sesti, G, Gnasso, A, Carallo, C, Scicchitano, C, Santini, C, Calbucci, G, Ripani, R, Corsi, L, Corsi, S, Romeo, F, Asprino, V, Donnarumma, G, Tizio, B, Clemente, G, Tomasi, F, Dozio, N, Mannucci, E, Lamanna, C, Cignarelli, M, Macchia, Ol, Fariello, S, Cordera, R, Mazzucchelli, C, Pupillo, M, Zugaro, A, Bosco, A, De Luca, A, Iannarelli, R, Giuliani, A, Polidoro, L, Sperandio, A, Sciarretta, F, Raffaella, B, Venditti, C, Di Cianni, G, Goretti, C, Dolci, Ma, Bruselli, L, Mori, M, Baccetti, F, Gregori, G, Venezia, A, Cucinotta, D, Pintaudi, B, Ragonese, F, Pata, P, Piatti, Pm, Luccotti, P, Orsi, E, Bonomo, M, Menicatti, L, Turco, Aa, Ciano, O, Vallefuoco, P, Corigliano, G, Pentangelo, C, Petraroli, E, Auletta, P, Carbonara, O, Capobianco, G, Caiazzo, G, Angiulli, B, De Simone, G, Michele, C, Mastrilli, V, Nunziata, G, Romano, G, Gaeta, I, Sorrentino, T, Iovine, C, Nappi, F, Paolisso, Giuseppe, Rizzo, Maria Rosaria, Avogaro, A, Vedovato, M, Lapolla, A, Sartore, G, Burlina, S, Chilelli, Nc, Galluzzoy, A, Giordano, C, Torregrossa, V, Arsenio, L, Dall'Aglio, E, Cioni, F, Babini, M, Moncastroppa, G, Perriello, G, Timi, A, Consoli, A, Ginestra, F, Zavaroni, D, Calzoni, F, Miccoli, R, Bianchi, C, Politi, S, Anichini, R, Tedeschi, A, Citro, G, Zampino, A, Rosa, S, Natale, M, Giocoli, Cl, Caruso, E, Tramontano, L, Imbroinise, A, Perna, Cd, Calabrese, M, Zogheri, A, Luberto, A, Ballardini, G, Babini, Ac, Zannoni, C, Pugliese, G, Salvi, L, Mazzitelli, G, Zappaterreno, A, Frontoni, S, Ventricini, A, Lauro, D, Galli, A, Rinaldi, Me, Leotta, S, Fontana, L, Goretti, S, Pozzilli, P, Leonetti, F, Morano, S, Filetti, S, Cosmo, Sd, Bacci, S, Palena, Ap, Calatola, P, Capuano, G, Amelia, U, Dotta, F, Guarino, E, Ceccarelli, E, Lalli, C, Scarponi, M, Forte, E, Potenziani, S, Perin, Pc, Marena, S, Zucco, C, Perotto, M, Bossi, A, Filopanti, M, Grimaldi, F, Tonutti, L, Cavarape, A, Cigolini, M, Pichiri, I, Brangani, C, Tomasetto, E, Capra, C, Cigolini M., Author information, Vaccaro, Olga, Masulli, Maria, Rivellese, ANGELA ALBAROSA, Riccardi, Gabriele, Giorda, C, Maggioni, A, Rivellese, A, Giorda, CB, Maggioni, AP, and Rivellese, AA

Subjects
Blood Glucose, Male, BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA, Endocrinology, Diabetes and Metabolism, pioglitazone, sulfonylurea, type 2 diabetes, metformin, cardiovascular events, Medicine (miscellaneous), Type 2 diabetes, Settore MED/13 - Endocrinologia, Body Mass Index, law.invention, Randomized controlled trial, Risk Factors, law, Surveys and Questionnaires, Cardiovascular Disease, pioglitazone, piogllitazone, Stroke, Diabetes, Therapy, Pioglitazone, Nutrition and Dietetics, Diabetes, Thiazolidinedione, cardiovascular events, Type 2 Diabetes Mellitus, sulphonylureas, Middle Aged, Metformin, Sulfonylurea Compound, Treatment Outcome, Tolerability, Cardiovascular Diseases, Drug Therapy, Combination, Female, type 2 diabetes, Cardiology and Cardiovascular Medicine, Human, medicine.drug, medicine.medical_specialty, Endpoint Determination, sulfonylurea, cardiovascualr event, Sudden death, Follow-Up Studie, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, sulfonylureas, interventio trial, randomized controlled trial, Aged, Hypoglycemic Agent, Questionnaire, business.industry, Risk Factor, medicine.disease, Surgery, Sulfonylurea Compounds, Diabetes Mellitus, Type 2, Quality of Life, Thiazolidinediones, Therapy, business, metformin, Pioglitazone, Follow-Up Studies
Abstract

Background and aims Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with metformin, the addition of a sulfonylurea or pioglitazone are equally plausible options to improve glycemic control. However, these drugs have profound differences in their mechanism of action, side effects, and impact on cardiovascular risk factors. A formal comparison of these two therapies in terms of cardiovascular morbidity and mortality is lacking. The TOSCA.IT study was designed to explore the effects of adding pioglitazone or a sulfonylurea on cardiovascular events in type 2 diabetic patients inadequately controlled with metformin. Methods Multicentre, randomized, open label, parallel group trial of 48 month duration. Type 2 diabetic subjects, 50–75 years, BMI 20–45 Kg/m 2 , on secondary failure to metformin monotherapy will be randomized to add-on a sulfonylurea or pioglitazone. The primary efficacy outcome is a composite endpoint of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and unplanned coronary revascularization. Principal secondary outcome is a composite ischemic endpoint of sudden death, fatal and non-fatal myocardial infarction and stroke, endovascular or surgical intervention on the coronary, leg or carotid arteries, major amputations. Side effects, quality of life and economic costs will also be evaluated. Efficacy, safety, tolerability, and study conduct will be monitored by an independent Data Safety Monitoring Board. End points will be adjudicated by an independent external committee. Conclusions TOSCA.IT is the first on-going study investigating the head-to-head comparison of adding a sulfonylurea or pioglitazone to existing metformin treatment in terms of hard cardiovascular outcomes. Registration: Clinicaltrials.gov ID NCT00700856.

Published
2012

17. OSTEOPROTEGERINA E SINDROME METABOLICA

Author

Polidoro, L, DE SANTIS, V, Scipioni, R, Petrazzi, L, Matani, A, Pozone, M, Barnabei, R, Properzi, Giuliana, and Ferri, Claudio

Published
2011

18. HCV: LA PUNTA DI UN ICEBERG

Author

D'Aurelio, A, Mazza, A, Polidoro, L, Petrazzi, L, Ciarrocchi, G, Zullo, A, Striuli, R, Bentivoglio, D, Grassi, D, Casale, R, Properzi, Giuliana, Pasqualetti, P, and Ferri, Claudio

Published
2011

28. OSTEOPROTEGERIN AND METABOLIC SYNDROME

Author

Polidoro, L, STRUGLIA M, DE SANTIS V., Scipione, R, Petrarca, M, Matani, A, Pozone, T, Barnabei, R, Properzi, Giuliana, and Ferri, Claudio

Published
2010

33. HCV : LA PUNTA DI UN ICEBERG

Author

D'Aurelio, A, Mazza, A, Polidoro, L, Petrazzi, L, CIARROCCHI G, G., Zullo, A, BENTIVOGLIO E, STRIULI R., GRASSI D, ., Casale, R, Properzi, Giuliana, Pasqualetti, P, and Ferri, C. C.

Published
2008

38. Oral Glucose Load Acutely Impairs Endothelial Function and Arterial Stiffness in Healthy Subjects: an Effect Prevented by Short-Term Administration of Flavanol-Rich Dark Chocolate

Author

Grassi, D, primary, Desideri, G, additional, Lippi, C, additional, Necozione, S, additional, DʼAurelio, A, additional, Petrazzi, L, additional, Polidoro, L, additional, Mazza, A, additional, Properzi, G, additional, Blumberg, J, additional, and Ferri, C, additional

Published
2007
Full Text
View/download PDF

41. Causes of hospitalisation before and after the 2009 L' Aquila earthquake.

Author

Petrazzi, L., Striuli, R., Polidoro, L., Petrarca, M., Scipioni, R., Struglia, M., Giorgini, P., Necozione, S., Festuccia, V., and Ferri, C.

Subjects
CHI-squared test, FISHER exact test, HOSPITAL care, LENGTH of stay in hospitals, HOSPITAL admission & discharge, NATURAL disasters, PATIENTS, T-test (Statistics), DATA analysis software, DESCRIPTIVE statistics
Abstract

On 6 April 2009, an earthquake struck L' Aquila. The San Salvatore Hospital was evacuated, and a field hospital was built. The study aimed to assess the epidemiologic impact of the earthquake through the analysis of patient population admitted to the field hospital during a 2-month period following the disaster. We retrospectively evaluated causes of hospitalisation and demographic data of patients admitted to (i) the Division of Internal Medicine and (ii) the Division of Emergency Medicine of the field hospital from 6 April, 2009 to 29 May, 2009. All data were compared with the admissions made at the same divisions of the San Salvatore Hospital during the same period of previous year. (i) Patient group ( n = 102) and comparison group ( n = 108). Mean patient age was higher, patients living in L' Aquila were more numerous, while mean length of stay was lower after than before the earthquake. Infectious diseases increased, while 'other' diseases decreased after the disaster both in admission and in discharge diagnoses. Gastroenterological diseases decreased with the earthquake but only in admission diagnoses. (ii) Patient group ( n = 5255) and comparison group ( n = 6564). Triage codes changed with the earthquake. Cardiovascular, psychiatric, gynaecological, infectious and chronic diseases increased, while pneumologic, gastroenterological, traumatic and 'other' diseases decreased after the quake. The number of hospitalised patients decreased with the tremor, while those discharged transferred to other hospitals and those who rejected hospitalisation increased. A natural disaster completely changes causes of hospitalisation in the Divisions of Internal and Emergency Medicine. These findings can be useful for the design of specific intervention programmes and for softening the detrimental effects of quakes. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

43. Changes in 24-h ambulatory blood pressure during the 2009 earthquake at L' Aquila: a new evaluation in the same patients.

Author

Striuli, R., Petrazzi, L., Giorgini, P., Petrarca, M., Pantoli, F., Polidoro, L., Properzi, G., Pasqualetti, P., Desideri, G., Ferri, C., and Parati, G.

Subjects
BLOOD pressure, NATURAL disasters, PATIENT monitoring
Abstract

The article discusses data obtained through 24-hours ambulatory blood pressure monitoring (ABPM) in two hypertensive patients during the 2009 earthquake of L'Aquila. It offers a graphical representation of 24-hour ABPM in the two patients such as patient A, and Patient B, that was recorded during the earthquake and after two years. It concludes as cardiovascular care must be raised both in the short and long term after an earthquake.

Published
2013
Full Text
View/download PDF

45. Changes in 24-h ambulatory blood pressure during the 2009 earthquake at L’Aquila: a new evaluation in the same patients

Author

Paolo Giorgini, Claudio Ferri, L. Petrazzi, Rinaldo Striuli, L. Polidoro, Giuliana Properzi, Giovambattista Desideri, Gianfranco Parati, Paolo Pasqualetti, Marco Petrarca, F. Pantoli, Striuli, R, Petrazzi, L, Giorgini, P, Petrarca, M, Pantoli, F, Polidoro, L, Properzi, G, Pasqualetti, P, Desideri, G, Ferri, C, and Parati, G

Subjects
L aquila, medicine.medical_specialty, Ambulatory blood pressure, business.industry, Internal Medicine, medicine, MEDLINE, Blood pressure monitoring, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Hypertension diagnosis, Intensive care medicine, business, ambulatory blood pressure, earthquake
Published
2013

46. Angiotensin-converting-enzyme inhibition counteracts angiotensin II-mediated endothelial cell dysfunction by modulating the p38/SirT1 axis.

Author

Marampon F, Gravina GL, Scarsella L, Festuccia C, Lovat F, Ciccarelli C, Zani BM, Polidoro L, Grassi D, Desideri G, Evangelista S, and Ferri C

Subjects
Apoptosis, Captopril analogs & derivatives, Captopril pharmacology, Cell Nucleus metabolism, Cell Survival, Endothelial Cells metabolism, Gene Expression Regulation, Human Umbilical Vein Endothelial Cells, Humans, Imidazoles pharmacology, MAP Kinase Kinase 6 metabolism, Oxidative Stress, Pyridines pharmacology, Reactive Oxygen Species, Superoxides metabolism, Angiotensin II metabolism, Angiotensin-Converting Enzyme Inhibitors pharmacology, Endothelial Cells cytology, Sirtuin 1 metabolism, p38 Mitogen-Activated Protein Kinases metabolism
Abstract

Objective: Oxidative stress has been linked to endothelial dysfunction and angiotensin II stimulates the reactive oxygen species production contributing to several cardiovascular diseases. We have studied the chain of events induced by angiotensin-converting-enzyme (ACE) activation in vascular umbilical vein endothelial cells (HUVECs) by using an ACE inhibitor such as zofenoprilat., Methods: We used specific assay to measure the superoxide anion production, tetrazolium bromide (MTT) assay for cell viability, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay for cell apoptosis, and western blot for protein analysis in the study., Results: Zofenoprilat counteracts the superoxide anion production and cell apoptosis induced by angiotensin I treatment by blocking the extrinsic caspase cascade, NF-kB and p38 activation. p38 inhibitor SB203580 reverted the angiotensin II oxidant effects while the p38 constitutively activation, by MKK6 transfection, abrogated the zofenoprilat effects. Characterizing the zofenoprilat downstream effector we found that zofenoprilat reverted the SirT-1 downregulation induced by angiotensin II. p38 activation by angiotensin II was strictly correlated with SirT1 protein downregulation; SB203580 significantly prevented SirT1 downregulation induced by angiotensin II while the p38 constitutive activation abolished SIRT1 protein basal levels. p38 directly bound SirT1 sequestering it in the cytoplasm. SirT1 inhibition by sirtinol annulled zofenoprilat action while SirT1 overexpression reverted the cytotoxic effects of angiotensin II. Finally, zofenoprilat negatively controlled angiotensin I receptor protein expression through SirT1., Conclusion: The p38-SirT1 axis is found markedly relevant in modulating the cardiovascular benefit deriving from ACE-inhibitors and might represent a novel target for innovative drugs in cardiovascular prevention.

Published
2013
Full Text
View/download PDF

47. Vitamin D protects human endothelial cells from H₂O₂ oxidant injury through the Mek/Erk-Sirt1 axis activation.

Author

Polidoro L, Properzi G, Marampon F, Gravina GL, Festuccia C, Di Cesare E, Scarsella L, Ciccarelli C, Zani BM, and Ferri C

Subjects
Apoptosis drug effects, Caspases metabolism, Cells, Cultured, Cytoprotection, Dose-Response Relationship, Drug, Enzyme Activation, Extracellular Signal-Regulated MAP Kinases antagonists & inhibitors, Extracellular Signal-Regulated MAP Kinases genetics, Histone Deacetylase Inhibitors pharmacology, Human Umbilical Vein Endothelial Cells enzymology, Human Umbilical Vein Endothelial Cells pathology, Humans, MAP Kinase Kinase Kinases antagonists & inhibitors, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 metabolism, Phosphorylation, Protein Kinase Inhibitors pharmacology, RNA Interference, Signal Transduction drug effects, Sirtuin 1 antagonists & inhibitors, Superoxides metabolism, Time Factors, Transfection, Antioxidants pharmacology, Extracellular Signal-Regulated MAP Kinases metabolism, Human Umbilical Vein Endothelial Cells drug effects, Hydrogen Peroxide toxicity, MAP Kinase Kinase Kinases metabolism, Oxidative Stress drug effects, Sirtuin 1 metabolism, Vitamin D pharmacology
Abstract

Endothelium homeostasis alterations govern the pathogenesis of cardiovascular diseases. Several studies show that vitamins anti-oxidant proprieties rescue the endothelial functions adversely affected by oxidative stress in several diseases. We investigated the vitamin D anti-oxidant potential in human endothelial cells exposed to H2O2 oxidative stress. Vitamin D protected endothelial cells against H2O2 oxidative stress counteracting the superoxide anion generation, the apoptosis and blocking the extrinsic caspase cascade by positively controlling phospho-active ERKs level. MEKs/ERKs inhibitor U0126 reverted the vitamin D anti-oxidant effects. Characterizing the vitamin D downstream effector, we found that vitamin D up-regulated SirT-1 and reverted the SirT-1 down-regulation induced by H2O2. ERKs activation by vitamin D strictly correlated with SirT-1 protein accumulation since both MEKs/ERKs inhibition and ERK1/2 silencing decreased SIRT-1. SirT-1 inhibition by Sirtinol reverted the vitamin D anti-oxidant effects. Thus, vitamin D significantly reduced the endothelial malfunction and damage caused by oxidative stress, through the activation of MEKs/ERKs/SirT-1 axis.

Published
2013
Full Text
View/download PDF

48. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.

Author

Marampon F, Gravina GL, Di Rocco A, Bonfili P, Di Staso M, Fardella C, Polidoro L, Ciccarelli C, Festuccia C, Popov VM, Pestell RG, Tombolini V, and Zani BM

Subjects
Animals, Cell Line, Tumor, Combined Modality Therapy, Down-Regulation drug effects, Female, Humans, Mice, Mice, Nude, Mitogen-Activated Protein Kinase Kinases genetics, Mitogen-Activated Protein Kinase Kinases metabolism, Rhabdomyosarcoma enzymology, Rhabdomyosarcoma genetics, Signal Transduction, Xenograft Model Antitumor Assays, Butadienes pharmacology, DNA Repair drug effects, Enzyme Inhibitors pharmacology, Mitogen-Activated Protein Kinase Kinases antagonists & inhibitors, Nitriles pharmacology, Radiation-Sensitizing Agents pharmacology, Rhabdomyosarcoma drug therapy, Rhabdomyosarcoma radiotherapy
Abstract

Multimodal treatment has improved the outcome of many solid tumors, and in some cases the use of radiosensitizers has significantly contributed to this gain. Activation of the extracellular signaling kinase pathway (MEK/ERK) generally results in stimulation of cell growth and confers a survival advantage playing the major role in human cancer. The potential involvement of this pathway in cellular radiosensitivity remains unclear. We previously reported that the disruption of c-Myc through MEK/ERK inhibition blocks the expression of the transformed phenotype; affects in vitro and in vivo growth and angiogenic signaling; and induces myogenic differentiation in the embryonal rhabdomyosarcoma (ERMS) cell lines (RD). This study was designed to examine whether the ERK pathway affects intrinsic radiosensitivity of rhabdomyosarcoma cancer cells. Exponentially growing human ERMS, RD, xenograft-derived RD-M1, and TE671 cell lines were used. The specific MEK/ERK inhibitor, U0126, reduced the clonogenic potential of the three cell lines, and was affected by radiation. U0126 inhibited phospho-active ERK1/2 and reduced DNA protein kinase catalytic subunit (DNA-PKcs) suggesting that ERKs and DNA-PKcs cooperate in radioprotection of rhabdomyosarcoma cells. The TE671 cell line xenotransplanted in mice showed a reduction in tumor mass and increase in the time of tumor progression with U0126 treatment associated with reduced DNA-PKcs, an effect enhanced by radiotherapy. Thus, our results show that MEK/ERK inhibition enhances radiosensitivity of rhabdomyosarcoma cells suggesting a rational approach in combination with radiotherapy., (©2010 AACR.)

Published
2011
Full Text
View/download PDF

50. Cardiovascular risk and cardiometabolic protection: role of glitazones.

Author

Petrazzi L, Grassi D, Polidoro L, D'Aurelio A, Croce G, Properzi G, Tiberti S, Desideri G, and Ferri C

Subjects
Cardiovascular Diseases etiology, Cardiovascular Diseases mortality, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Global Health, Humans, PPAR gamma, Pioglitazone, Risk Factors, Rosiglitazone, Survival Rate, Treatment Outcome, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 drug therapy, Hypoglycemic Agents therapeutic use, Insulin blood, Thiazolidinediones therapeutic use
Abstract

Thiazolidinediones (TZDs) are widely used in the type 2 diabetes mellitus (DMT2) treatment but have also been tested in cardiovascular prevention. DMT2 is associated with a marked increment in cardiovascular risk, and its prevention represents a main target in cardiometabolic protection. Both Troglitazone (Troglitazone in Prevention of Diabetes study) and Rosiglitazone (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication study) significantly reduced new-onset diabetes. A similar topic will be investigated with pioglitazone (Actos Now for Prevention of Diabetes). In the Prospective Pioglitazone Clinical Trial in Macrovascular events the primary end point (all-cause mortality, nonfatal myocardial infarction, stroke, acute coronary syndromes, endovascular or surgical intervention in the coronary/leg arteries and amputation above ankles) was unaffected, whereas the secondary one (all-cause mortality, nonfatal myocardial infarction and stroke) was reduced by pioglitazone (-16%, p=0.027) compared to placebo in 5,238 patients with DMT2 and macrovascular disease. In contrast, a meta-analysis (Nissen and Wolski, N Engl J Med. 2007;356:2457-2471) reported that rosiglitazone treatment is associated with a significant increase in myocardial infarction risk (p=0.03) and a borderline significant increase in the risk of death from cardiovascular causes (p=0.06). Nevertheless, the possibility that rosiglitazone might affect cardiovascular events should be evaluated by the ongoing trial Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD). Interim findings early from RECORD did not show significant differences between the rosiglitazone and the control group regarding myocardial infarction and death from cardiovascular and any cause. Additional large-scale trials are awaited to clarify the of role TZDs in cardiovascular outcomes.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results